INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Submitted on December 3, 2007

Sheet 1 of 2

Complete if Known	
Application No.	10/525,301
Filing Date	August 29, 2005
First Named Inventor	David Jackson
Art Unit	1654
Examiner Name	David Lukton
Attorney Docket Number	23133-09966US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document No. Number – Kind Code[2] (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-6,024,964	02-15-2000	Jung et al.
	A2	US-5,700,910	12-23-1997	Metzger et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	B1	WO – 93/22343	11-11-1993	Feller University; Tam, J. (For U.S. Only)	

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[6]
	C1	BENMOHAMED, L., et al., "Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees," Eur. J. Immunol, 1997, Pages 1242-1253, Vol. 27.	
	C2	BENMOHAMED, L., et al., "High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules," Vaccine 18, 2000, Pages 2843-2855	
	C3	BOECKLER, C., ET AL., "Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes," Eur. J. Immunol, 1999, Pages 2297-2308, Vol. 29.	
	C4	DEPREZ, B., ET AL., "Pimelautide or Trimexautide as Built-in Adjuvants Associated with an HIV-1-Derived Peptide: Synthesis and in Vivo Induction of Antibody and Virus-Specific Cytotoxic T-Lymphocyte-Mediated Response," J. Med. Chem., 1995, Pages 459-465, Vol. 38.	
	C5	DEPREZ, B., ET AL., "Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL," Vaccine, 1996, Pages 375-382, Vol. 14, No. 5	
	C6	DERES, K., ET AL., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," Nature, November 30, 1989, Pages 561-564, Vol. 342.	
	C7	GHOSH, S., ET AL., "Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines," International Immunology, 1999, Pages 1103-1110, Vol. 11.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application No.	10/525,301
				Filing Date	August 29, 2005
				First Named Inventor	David Jackson
				Art Unit	1654
Submitted on December 3, 2007				Examiner Name	David Lukton
Sheet	2	of	2	Attorney Docket Number	23133-09966US

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[6]
	C8	JUNG, G., ET AL., "Increased Production of Specific Antibodies by Presentation of the Antigen Determinants with Covalently Coupled Lipopeptide Mitogens," Angew Chem, Int. Ed. Engl., 1985, Pages 872-273, No. 10.	
	C9	MARTINON, F., ET AL., "Immunization Of Mice With Lipopeptides Bypasses The Prerequisite For Adjuvant, Immune Response to Lipopeptides," The Journal of Immunology, 1992, Pages 3416-3422, Vol. 149, No. 10.	
	C10	METZGER, J., ET AL., "Synthetic S-(2, 3-Dihydroxypropyl)-cysteinyl Peptides Derived from the N-terminus of the Cytochrome Submit of the Photoreaction Centre of Rhodopseudomonas viridis Enhance Murine Splenocyte Proliferation, Novel Synthetic Lipopeptides Activate Splenocytes," Journal of Peptide Science, 1995, Pages 184-190, Vol. 3.	
	C11	MÜHLRADT, P., ET AL., "Isolation, Structure Elucidation, and Synthesis of a Macrophage Stimulatory Lipopeptide from Mycoplasma fermentans Acting at Picomolar Concentration," J. Exp. Med., June 2, 1997, Pages 1951-1958, Volume 185, No. 11	
	C12	MÜHLRADT, P., ET AL., "Structure and Specific Activity of Macrophage-Stimulating Lipopeptides from Mycoplasma hyorhinis," Infection and Immunity, October 1998, Pages 4804-4810, Vol. 66, No. 10.	
	C13	NARDIN, E. H., ET AL., "A Totally Synthetic Polyoxime Malaria Vaccine Containing Plasmodium falciparum B Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types," The Journal of Immunology, 2001, Pages 481-489, Vol. 166.	
	C14	NARDIN, E. H., ET AL., "Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-Cell epitope of CS protein," Vaccine, 1998, Pages 590-600, Vol. 16, No. 6.	
	C15	OBERT, M., ET AL., "Protection of mice against SV40 tumours by Pam_3Cys conjugated with SV40 T antigen-derived peptide, K(698)-T(708)," Vaccine, 1998, Pages 161-169, Vol. 16, No. 2/3.	
	C16	SAUZET, J.-P., ET AL., "Long-lasting anti-viral cytotixic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides," Vaccine, 1995, Pages 1339-1345, Vol. 13, No. 14.	
	C17	TOYOKUNI, T., ET AL., "Synthetic Vaccines: Synthesis of a Dimeric Tn Antigen-Lipopeptide Conjugate that Elicits Immune Responses against Tn-Expressing Glycoproteins," J. Am. Chem. Soc., 1994, Pages 395-396, Vol. 116.	
	C18	WIESMÜLLER, K.-H., ET AL., "Synthesis of the Mitogenic S-[2, 3-Bis(palmitoyloxy) propyl]-N-palmitoylpentapeptide from Escherichia coli Lipoprotein," Hoppe-Seyler's Z. Physiol. Chem., 1983, Pages 593-606, Bd. 364.	
	C19	WIESMÜLLER, K.-H., ET AL., "Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator," Vaccine, February 1989, Pages 29-33, Vol. 7.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.